RT Journal Article
SR Electronic
T1 THE METABOLIC FATE OF MEBUTAMATE (CAPLA)
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP 5
OP 9
VO 136
IS 1
A1 J. F. Douglas
A1 B. J. Ludwig
A1 T. Ginsberg
A1 F. M. Berger
YR 1962
UL http://jpet.aspetjournals.org/content/136/1/5.abstract
AB Mebutamate is absorbed rapidly into the bloodstream of man, reaching a peak concentration between the first and second hours after oral administration. The metabolism of mebutamate leads to at least three urinary end-products: unchanged drug present in small quantities, a hydroxylated derivative, 2-methyl-2-(β-hydroxyl-α-methylpropyl)-1,3-propanediol dicarbamate, which is the primary metabolite and a glucuronide conjugate.